TG Therapeutics(TGTX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance Second quarter 2024 U.S. BRIUMVI net revenue of $72.6 million Raising full year 2024 U.S. BRIUMVI net revenue target to approximately$290 - $300 million Cash flow positive for second quarter 2024 Establishes$250 million credit facility to repay existing debt and to buy back up to $100 million of common stock under a share repurchase program Initiated phase 1 study in ...